September 15, 2004Cancer Research
Inducible Silencing of KILLER/DR5 In vivo Promotes Bioluminescent Colon Tumor Xenograft Growth and Confers Resistance to Chemotherapeutic Agent 5-Fluorouracil
Authors
Discussion
Loading...
Member takes
Implication
Preclinical study demonstrates that silencing KILLER/DR5 accelerates colon tumor growth and confers 5-fluorouracil resistance in mice, highlighting its key role in tumor suppression.
Key Points
- To determine the in vivo contribution of the tumor suppressor KILLER/DR5 to colon tumor growth inhibition and its role in modulating sensitivity to 5-fluorouracil chemotherapy.
- Engineered stable human colon cancer cell lines harboring a doxycycline-inducible RNA interference system to conditionally knock down KILLER/DR5.
- Inoculated mice to form bioluminescent colon tumor xenografts and administered doxycycline to induce gene silencing in vivo alongside 5-fluorouracil treatment.
- Doxycycline-induced silencing of KILLER/DR5 in vivo markedly accelerated the growth of bioluminescent colon tumor xenografts.
- Ablation of KILLER/DR5 function conferred resistance to the chemotherapeutic agent 5-fluorouracil in tumor-bearing mice.
Cite This Study
Wang et al. (2004) studied this question.